Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia
Objective To describe the features of ETV6::ABL1 AML as well as the clinical treatment and outcomes. Methods Clinical data were collected from three patients diagnosed with ETV6::ABL1 AML at Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital. Their clinical and laboratory features were an...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2024-05, Vol.119 (5), p.564-572 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 572 |
|---|---|
| container_issue | 5 |
| container_start_page | 564 |
| container_title | International journal of hematology |
| container_volume | 119 |
| creator | Xue, Song Sun, Hui-Peng Huang, Xiao-Bing Chen, Xue Wang, Tong Ma, Wei Tian, Yao Pan, Zhi-Lan Li, Li-Hong Zhang, Lu Liu, Hong-Xing Cao, Xing-Yu |
| description | Objective
To describe the features of ETV6::ABL1 AML as well as the clinical treatment and outcomes.
Methods
Clinical data were collected from three patients diagnosed with ETV6::ABL1 AML at Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital. Their clinical and laboratory features were analyzed, and the treatment process and outcomes were described. Ten reported cases of ETV6::ABL1 AML from the literature were also included for analysis.
Results
The median age of the patients was 34 years, and 2 patients were male. No patient had a history of blood disorders before diagnosis. After relapse, they were referred to our hospital, where the ETV6::ABL1 gene was detected. Unfortunately, Patient 1 died rapidly after leukemia relapse due to severe infection. Patients 2 and 3 received salvage therapy with a dasatinib-containing regimen, followed by allo-HSCT, and are currently alive and disease-free.
Conclusion
ETV6::ABL1 is a rare but recurrent genetic aberration in AML, and the combined use of fluorescence in situ hybridization and PCR can better identify this fusion gene. Patients carrying ETV6::ABL1 have a high relapse rate and a poor prognosis. TKIs are a reasonable treatment option for this group, and allo-HSCT may be curative. |
| doi_str_mv | 10.1007/s12185-024-03729-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2937705670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2937705670</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-663f94cfb698b852efa41a24941e7f5d22aae5be8f40f87081beed68e39c7b3f3</originalsourceid><addsrcrecordid>eNp9kE1vFDEMhiMEokvhD3BAkbhwSXG-JklvZVWg0kq9tL1GmVmnpMzHkswU9d-TdgtIPfRkWX782noIec_hiAOYz4ULbjUDoRhIIxxzL8iK20YzaYx6SVbghGbacDggb0q5AeAGlHlNDqRVihujV8Svf4QcuhlzKnPqCg3jlvap9mFeMtKMtwl_0ynS04ur5vj45MuG07iUNI30Gkdku6mkOd0iDd0yIx3usJ9SjcDlJw4pvCWvYugLvnush-Ty6-nF-jvbnH87W59sWCdFM7OmkdGpLraNs63VAmNQPAjlFEcT9VaIEFC3aKOCaA1Y3iJuG4vSdaaVUR6ST_vcXZ5-LVhmP6TSYd-HEaeleOGqE9CNgYp-fILeTEse63deggZtwYKrlNhTXZ5KyRj9Lqch5DvPwd_r93v9vur3D_r9_dKHx-ilHXD7b-Wv7wrIPVDqaLzG_P_2M7F_ANUhkAc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3050580809</pqid></control><display><type>article</type><title>Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Xue, Song ; Sun, Hui-Peng ; Huang, Xiao-Bing ; Chen, Xue ; Wang, Tong ; Ma, Wei ; Tian, Yao ; Pan, Zhi-Lan ; Li, Li-Hong ; Zhang, Lu ; Liu, Hong-Xing ; Cao, Xing-Yu</creator><creatorcontrib>Xue, Song ; Sun, Hui-Peng ; Huang, Xiao-Bing ; Chen, Xue ; Wang, Tong ; Ma, Wei ; Tian, Yao ; Pan, Zhi-Lan ; Li, Li-Hong ; Zhang, Lu ; Liu, Hong-Xing ; Cao, Xing-Yu</creatorcontrib><description>Objective
To describe the features of ETV6::ABL1 AML as well as the clinical treatment and outcomes.
Methods
Clinical data were collected from three patients diagnosed with ETV6::ABL1 AML at Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital. Their clinical and laboratory features were analyzed, and the treatment process and outcomes were described. Ten reported cases of ETV6::ABL1 AML from the literature were also included for analysis.
Results
The median age of the patients was 34 years, and 2 patients were male. No patient had a history of blood disorders before diagnosis. After relapse, they were referred to our hospital, where the ETV6::ABL1 gene was detected. Unfortunately, Patient 1 died rapidly after leukemia relapse due to severe infection. Patients 2 and 3 received salvage therapy with a dasatinib-containing regimen, followed by allo-HSCT, and are currently alive and disease-free.
Conclusion
ETV6::ABL1 is a rare but recurrent genetic aberration in AML, and the combined use of fluorescence in situ hybridization and PCR can better identify this fusion gene. Patients carrying ETV6::ABL1 have a high relapse rate and a poor prognosis. TKIs are a reasonable treatment option for this group, and allo-HSCT may be curative.</description><identifier>ISSN: 0925-5710</identifier><identifier>ISSN: 1865-3774</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-024-03729-9</identifier><identifier>PMID: 38441775</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Abl1 gene ; Acute myeloid leukemia ; Adult ; ETS Translocation Variant 6 Protein ; Female ; Fluorescence in situ hybridization ; Fusion protein ; Gene fusion ; Health services ; Hematology ; Hematopoietic Stem Cell Transplantation ; Hospitals ; Humans ; Leukemia ; Leukemia, Myeloid, Acute - diagnosis ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - therapy ; Literature reviews ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncogene Proteins, Fusion - genetics ; Oncology ; Original Article ; Patients ; Proto-Oncogene Proteins c-abl - genetics ; Proto-Oncogene Proteins c-ets - genetics ; Repressor Proteins - genetics ; Treatment Outcome</subject><ispartof>International journal of hematology, 2024-05, Vol.119 (5), p.564-572</ispartof><rights>Japanese Society of Hematology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. Japanese Society of Hematology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-663f94cfb698b852efa41a24941e7f5d22aae5be8f40f87081beed68e39c7b3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-024-03729-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-024-03729-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38441775$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xue, Song</creatorcontrib><creatorcontrib>Sun, Hui-Peng</creatorcontrib><creatorcontrib>Huang, Xiao-Bing</creatorcontrib><creatorcontrib>Chen, Xue</creatorcontrib><creatorcontrib>Wang, Tong</creatorcontrib><creatorcontrib>Ma, Wei</creatorcontrib><creatorcontrib>Tian, Yao</creatorcontrib><creatorcontrib>Pan, Zhi-Lan</creatorcontrib><creatorcontrib>Li, Li-Hong</creatorcontrib><creatorcontrib>Zhang, Lu</creatorcontrib><creatorcontrib>Liu, Hong-Xing</creatorcontrib><creatorcontrib>Cao, Xing-Yu</creatorcontrib><title>Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Objective
To describe the features of ETV6::ABL1 AML as well as the clinical treatment and outcomes.
Methods
Clinical data were collected from three patients diagnosed with ETV6::ABL1 AML at Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital. Their clinical and laboratory features were analyzed, and the treatment process and outcomes were described. Ten reported cases of ETV6::ABL1 AML from the literature were also included for analysis.
Results
The median age of the patients was 34 years, and 2 patients were male. No patient had a history of blood disorders before diagnosis. After relapse, they were referred to our hospital, where the ETV6::ABL1 gene was detected. Unfortunately, Patient 1 died rapidly after leukemia relapse due to severe infection. Patients 2 and 3 received salvage therapy with a dasatinib-containing regimen, followed by allo-HSCT, and are currently alive and disease-free.
Conclusion
ETV6::ABL1 is a rare but recurrent genetic aberration in AML, and the combined use of fluorescence in situ hybridization and PCR can better identify this fusion gene. Patients carrying ETV6::ABL1 have a high relapse rate and a poor prognosis. TKIs are a reasonable treatment option for this group, and allo-HSCT may be curative.</description><subject>Abl1 gene</subject><subject>Acute myeloid leukemia</subject><subject>Adult</subject><subject>ETS Translocation Variant 6 Protein</subject><subject>Female</subject><subject>Fluorescence in situ hybridization</subject><subject>Fusion protein</subject><subject>Gene fusion</subject><subject>Health services</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - diagnosis</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Literature reviews</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncogene Proteins, Fusion - genetics</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Proto-Oncogene Proteins c-abl - genetics</subject><subject>Proto-Oncogene Proteins c-ets - genetics</subject><subject>Repressor Proteins - genetics</subject><subject>Treatment Outcome</subject><issn>0925-5710</issn><issn>1865-3774</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1vFDEMhiMEokvhD3BAkbhwSXG-JklvZVWg0kq9tL1GmVmnpMzHkswU9d-TdgtIPfRkWX782noIec_hiAOYz4ULbjUDoRhIIxxzL8iK20YzaYx6SVbghGbacDggb0q5AeAGlHlNDqRVihujV8Svf4QcuhlzKnPqCg3jlvap9mFeMtKMtwl_0ynS04ur5vj45MuG07iUNI30Gkdku6mkOd0iDd0yIx3usJ9SjcDlJw4pvCWvYugLvnush-Ty6-nF-jvbnH87W59sWCdFM7OmkdGpLraNs63VAmNQPAjlFEcT9VaIEFC3aKOCaA1Y3iJuG4vSdaaVUR6ST_vcXZ5-LVhmP6TSYd-HEaeleOGqE9CNgYp-fILeTEse63deggZtwYKrlNhTXZ5KyRj9Lqch5DvPwd_r93v9vur3D_r9_dKHx-ilHXD7b-Wv7wrIPVDqaLzG_P_2M7F_ANUhkAc</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Xue, Song</creator><creator>Sun, Hui-Peng</creator><creator>Huang, Xiao-Bing</creator><creator>Chen, Xue</creator><creator>Wang, Tong</creator><creator>Ma, Wei</creator><creator>Tian, Yao</creator><creator>Pan, Zhi-Lan</creator><creator>Li, Li-Hong</creator><creator>Zhang, Lu</creator><creator>Liu, Hong-Xing</creator><creator>Cao, Xing-Yu</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20240501</creationdate><title>Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia</title><author>Xue, Song ; Sun, Hui-Peng ; Huang, Xiao-Bing ; Chen, Xue ; Wang, Tong ; Ma, Wei ; Tian, Yao ; Pan, Zhi-Lan ; Li, Li-Hong ; Zhang, Lu ; Liu, Hong-Xing ; Cao, Xing-Yu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-663f94cfb698b852efa41a24941e7f5d22aae5be8f40f87081beed68e39c7b3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Abl1 gene</topic><topic>Acute myeloid leukemia</topic><topic>Adult</topic><topic>ETS Translocation Variant 6 Protein</topic><topic>Female</topic><topic>Fluorescence in situ hybridization</topic><topic>Fusion protein</topic><topic>Gene fusion</topic><topic>Health services</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - diagnosis</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Literature reviews</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncogene Proteins, Fusion - genetics</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Proto-Oncogene Proteins c-abl - genetics</topic><topic>Proto-Oncogene Proteins c-ets - genetics</topic><topic>Repressor Proteins - genetics</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xue, Song</creatorcontrib><creatorcontrib>Sun, Hui-Peng</creatorcontrib><creatorcontrib>Huang, Xiao-Bing</creatorcontrib><creatorcontrib>Chen, Xue</creatorcontrib><creatorcontrib>Wang, Tong</creatorcontrib><creatorcontrib>Ma, Wei</creatorcontrib><creatorcontrib>Tian, Yao</creatorcontrib><creatorcontrib>Pan, Zhi-Lan</creatorcontrib><creatorcontrib>Li, Li-Hong</creatorcontrib><creatorcontrib>Zhang, Lu</creatorcontrib><creatorcontrib>Liu, Hong-Xing</creatorcontrib><creatorcontrib>Cao, Xing-Yu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xue, Song</au><au>Sun, Hui-Peng</au><au>Huang, Xiao-Bing</au><au>Chen, Xue</au><au>Wang, Tong</au><au>Ma, Wei</au><au>Tian, Yao</au><au>Pan, Zhi-Lan</au><au>Li, Li-Hong</au><au>Zhang, Lu</au><au>Liu, Hong-Xing</au><au>Cao, Xing-Yu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>119</volume><issue>5</issue><spage>564</spage><epage>572</epage><pages>564-572</pages><issn>0925-5710</issn><issn>1865-3774</issn><eissn>1865-3774</eissn><abstract>Objective
To describe the features of ETV6::ABL1 AML as well as the clinical treatment and outcomes.
Methods
Clinical data were collected from three patients diagnosed with ETV6::ABL1 AML at Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital. Their clinical and laboratory features were analyzed, and the treatment process and outcomes were described. Ten reported cases of ETV6::ABL1 AML from the literature were also included for analysis.
Results
The median age of the patients was 34 years, and 2 patients were male. No patient had a history of blood disorders before diagnosis. After relapse, they were referred to our hospital, where the ETV6::ABL1 gene was detected. Unfortunately, Patient 1 died rapidly after leukemia relapse due to severe infection. Patients 2 and 3 received salvage therapy with a dasatinib-containing regimen, followed by allo-HSCT, and are currently alive and disease-free.
Conclusion
ETV6::ABL1 is a rare but recurrent genetic aberration in AML, and the combined use of fluorescence in situ hybridization and PCR can better identify this fusion gene. Patients carrying ETV6::ABL1 have a high relapse rate and a poor prognosis. TKIs are a reasonable treatment option for this group, and allo-HSCT may be curative.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>38441775</pmid><doi>10.1007/s12185-024-03729-9</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2024-05, Vol.119 (5), p.564-572 |
| issn | 0925-5710 1865-3774 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2937705670 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Abl1 gene Acute myeloid leukemia Adult ETS Translocation Variant 6 Protein Female Fluorescence in situ hybridization Fusion protein Gene fusion Health services Hematology Hematopoietic Stem Cell Transplantation Hospitals Humans Leukemia Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - therapy Literature reviews Male Medicine Medicine & Public Health Middle Aged Oncogene Proteins, Fusion - genetics Oncology Original Article Patients Proto-Oncogene Proteins c-abl - genetics Proto-Oncogene Proteins c-ets - genetics Repressor Proteins - genetics Treatment Outcome |
| title | Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A14%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20and%20literature%20review%20of%20ETV6::ABL1%20fusion%20gene-positive%20acute%20myeloid%20leukemia&rft.jtitle=International%20journal%20of%20hematology&rft.au=Xue,%20Song&rft.date=2024-05-01&rft.volume=119&rft.issue=5&rft.spage=564&rft.epage=572&rft.pages=564-572&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-024-03729-9&rft_dat=%3Cproquest_cross%3E2937705670%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3050580809&rft_id=info:pmid/38441775&rfr_iscdi=true |